What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Cancer research, Anaplastic lymphoma kinase, Lung cancer, Crizotinib and Cancer are his primary areas of study.
His biological study spans a wide range of topics, including Receptor tyrosine kinase, MSH6, Drug resistance and Gefitinib.
His Anaplastic lymphoma kinase research includes themes of Anaplastic large-cell lymphoma and ROS1.
To a larger extent, A. John Iafrate studies Pathology with the aim of understanding Lung cancer.
His Pathology research incorporates themes from Circulating tumor cell and Adenocarcinoma.
The study of Oncology and Internal medicine are components of his Crizotinib research.
His most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Detection of large-scale variation in the human genome. (2589 citations)
- Detection of large-scale variation in the human genome. (2589 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Cancer research, Internal medicine, Oncology, Pathology and Cancer.
His Cancer research research is multidisciplinary, relying on both Mutation, KRAS, Anaplastic lymphoma kinase and Immunology.
His research integrates issues of Crizotinib and ROS1 in his study of Anaplastic lymphoma kinase.
His Internal medicine research integrates issues from Gastroenterology and Bioinformatics.
The study incorporates disciplines such as Genotyping, Targeted therapy, Clinical trial and Metastasis in addition to Oncology.
As a part of the same scientific family, A. John Iafrate mostly works in the field of Pathology, focusing on Adenocarcinoma and, on occasion, Lung and Gene.
He most often published in these fields:
- Cancer research (35.37%)
- Internal medicine (31.63%)
- Oncology (27.55%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (31.63%)
- Antibody (4.76%)
- Oncology (27.55%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Antibody, Oncology, Severe acute respiratory syndrome coronavirus 2 and Serology.
His research links Genotyping with Internal medicine.
The Antibody study combines topics in areas such as Immune system and Virology.
His Oncology study combines topics from a wide range of disciplines, such as Molecular analysis, Treatment options, Clinical trial and Cancer.
He combines subjects such as Cancer research and Somatic cell with his study of Human brain.
A. John Iafrate carries out multidisciplinary research, doing studies in Cancer research and PDGFRA.
Between 2019 and 2021, his most popular works were:
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. (155 citations)
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. (90 citations)
- Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. (80 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His main research concerns Antibody, Severe acute respiratory syndrome coronavirus 2, Immunology, Immune system and Serology.
His study ties his expertise on Internal medicine together with the subject of Antibody.
His work on Neutralizing antibody, Seroconversion and Titer is typically connected to Persistence and Isotype as part of general Immunology study, connecting several disciplines of science.
His Immune system study combines topics in areas such as Potency, Seroprevalence, Neutralization and Cohort.
His Serology research incorporates elements of Biomarker, Positive test, Retrospective cohort study and Polymerase chain reaction.
A. John Iafrate has researched Humoral immunity in several fields, including Proinflammatory cytokine, Immunoglobulin G and Vaccination, Virology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
